Limitations of de novo peptide sequencing in resolving sequence ambiguity 

Sam van Puyenbroeck et al.

Nat Methods. 2026 Nov 3. doi: 10.1038/s41592-026-03301-9. Online ahead of print.

Published on November 3, 2026

Abstract

ABSTRACT

De novo peptide sequencing enables peptide identification from fragmentation spectra without relying on sequence databases. However, incomplete spectra create ambiguity, making unambiguous identification challenging. Recent deep learning advances have produced numerous de novo models that predict sequences and refine peptide-spectrum matches under such conditions. Yet, their relative strengths, weaknesses and ability to handle spectrum ambiguity remain unclear. Here we benchmark eight state-of-the-art models on three publicly available proteomics datasets, comparing performance using established metrics and quantifying inter-model agreement. We assess post-processing approaches, including iterative refinement, rescoring and reranking, for their ability to improve identification accuracy, and perform an error analysis to identify common mispredictions and their causes. Model performance varied, with considerable overlap of correct identifications. Post-processing yielded no or only modest improvements. Most sequencing errors were model-independent and driven by limited fragment ion coverage, a limitation also observed in database searches with large search spaces.

PMID:42977835 | DOI:10.1038/s41592-026-03301-9

 Read More

← Back to Publications
Xiaofei Chen et al.J Orthop Translat. 2026 Oct 25;61:101241. doi: 10.1016/j.jot.2026.101241. eCollection 2026 Nov.
Saeka Shimochi et al.Pharmaceuticals (Basel). 2026 Oct 10;19(10):1610. doi: 10.3390/ph19101610.
Kim Kreuze et al.Res Sq [Preprint]. 2026 Oct 5:rs.3.rs-11232673. doi: 10.21203/rs.3.rs-11232673/v1.
Prince Dadson et al.Int J Obes (Lond). 2026 Oct 16. doi: 10.1038/s41366-026-02243-8. Online ahead of print.
Jiaqi Yan et al.Biomaterials. 2026 Sep 30;338(Pt A):124669. doi: 10.1016/j.biomaterials.2026.124669. Online ahead of print.